Medicine and Dentistry
Pulmonary Hypertension
100%
Systemic Scleroderma
20%
Right Ventricular Function
15%
Cardiac Magnetic Resonance Imaging
15%
Scleroderma
11%
Hemodynamic
9%
Programmed Cell Death
9%
Endothelial Cell
8%
Lung Vascular Resistance
8%
Polycyclic Aromatic Hydrocarbon
8%
Disease
7%
Cardiac Catheterization
7%
Hypoxia
6%
Angiogenesis
6%
Transplantation
5%
Combination Therapy
5%
Endostatin
5%
Ambrisentan
5%
Tadalafil
5%
Semaxanib
5%
Afterload
5%
Right Ventricle
5%
Keyphrases
Pulmonary Arterial Hypertension
45%
Pulmonary Hypertension
35%
Right Ventricular Function
16%
Apoptosis
15%
Right Ventricular
14%
Caspase-3
10%
Tuberous Sclerosis Complex
8%
Hypertension Patients
7%
Cardiac Magnetic Resonance Imaging (cMRI)
7%
Systemic Sclerosis
7%
Right Ventricle
7%
Lung
7%
Pulmonary Artery Smooth muscle Cells (PASMCs)
6%
Scleroderma
5%
Xanthine Oxidase
5%
Upfront Combination Therapy
5%
Renal Tumor
5%
Tumor Cells
5%
Tricuspid Annular Plane Systolic Excursion (TAPSE)
5%
SU5416
5%
Aquaporin 1 (AQP1)
5%
American Thoracic Society
5%
Pulmonary Endothelium
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pulmonary Hypertension
46%
Hypoxia
14%
Systemic Sclerosis
10%
Mouse
9%
Scleroderma
8%
Xanthine Oxidase
8%
Disease
7%
Polycyclic Aromatic Hydrocarbon
7%
Caspase 3
6%
Protein Kinases
6%
Mitogen Activated Protein Kinase
5%
Combination Therapy
5%
Macrophage Migration Inhibition Factor
5%
Cigarette Smoke
5%
Ambrisentan
5%
Okadaic Acid
5%
Kidney Tumour
5%
Tadalafil
5%
Semaxanib
5%
